ImmunoGenix
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $175M
Overview
A synthetic biology platform for rapid discovery of fully human, multi-specific antibody therapeutics.
OncologyImmunology
Technology Platform
A synthetic biology platform utilizing cell-free ribosome display and AI to rapidly generate and optimize fully human, multi-specific antibodies from vast in vitro libraries.
Funding History
1Total raised:$175M
Series C$175M
Opportunities
To partner with big pharma to fill pipelines with novel multi-specific antibodies for complex diseases.
Risk Factors
Platform validation depends on advancing internal candidates to clinical proof-of-concept in competitive therapeutic areas.
Competitive Landscape
Operates in the crowded but high-growth antibody discovery sector, competing with both traditional display companies and AI-native drug discovery firms.